Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes

This article will review risankizumab, a monoclonal antibody targeting interleukin 23 (IL-23) for the treatment of moderate-to-severe Crohn’s disease. The article will detail the mechanism of action and dosing strategies. Efficacy in induction and maintenances will be reviewed from available clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Horst, Sara, Cross, Raymond K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899013/
https://www.ncbi.nlm.nih.gov/pubmed/36747585
http://dx.doi.org/10.2147/DDDT.S379446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899013/
https://www.ncbi.nlm.nih.gov/pubmed/36747585
http://dx.doi.org/10.2147/DDDT.S379446

Ejemplares similares